---
annotations:
- type: Pathway Ontology
  value: classic metabolic pathway
- type: Pathway Ontology
  value: peptide and protein metabolic pathway
authors:
- ReactomeTeam
- Anwesha
- Ryanmiller
- Eweitz
description: The family of Insulin like Growth Factor Binding Proteins (IGFBPs) share
  50% amino acid identity with conserved N terminal and C terminal regions responsible
  for binding Insulin like Growth Factors I and II (IGF I and IGF II). Most circulating
  IGFs are in complexes with IGFBPs, which are believed to increase the residence
  of IGFs in the body, modulate availability of IGFs to target receptors for IGFs,
  reduce insulin like effects of IGFs, and act as signaling molecules independently
  of IGFs. About 75% of circulating IGFs are in 1500 220 KDa complexes with IGFBP3
  and ALS. Such complexes are too large to pass the endothelial barrier. The remaining
  20 25% of IGFs are bound to other IGFBPs in 40 50 KDa complexes. IGFs are released
  from IGF:IGFBP complexes by proteolysis of the IGFBP. IGFs become active after release,
  however IGFs may also have activity when still bound to some IGFBPs. IGFBP1 is enriched
  in amniotic fluid and is produced in the liver under control of insulin (insulin
  suppresses production). IGFBP1 binding stimulates IGF function. It is unknown which
  if any protease degrades IGFBP1. IGFBP2 is enriched in cerebrospinal fluid; its
  binding inhibits IGF function. IGFBP2 is not significantly degraded in circulation.
  IGFB3, which binds most IGF in the body is enriched in follicular fluid and found
  in many other tissues. IGFBP 3 may be cleaved by plasmin, thrombin, Prostate specific
  Antigen (PSA, KLK3), Matrix Metalloprotease-1 (MMP1), and Matrix Metalloprotease-2
  (MMP2). IGFBP3 also binds extracellular matrix and binding lowers its affinity for
  IGFs. IGFBP3 binding stimulates the effects of IGFs. IGFBP4 acts to inhibit IGF
  function and is cleaved by Pregnancy associated Plasma Protein A (PAPPA) to release
  IGF. IGFBP5 is enriched in bone matrix; its binding stimulates IGF function. IGFBP5
  is cleaved by Pregnancy Associated Plasma Protein A2 (PAPPA2), ADAM9, complement
  C1s from smooth muscle, and thrombin. Only the cleavage site for PAPPA2 is known.
  IGFBP6 is enriched in cerebrospinal fluid. It is unknown which if any protease degrades
  IGFBP6.   View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=381426
  Reactome].
last-edited: 2021-05-11
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP2799
- /instance/WP2799
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP2799.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: The family of Insulin like Growth Factor Binding Proteins (IGFBPs)
    share 50% amino acid identity with conserved N terminal and C terminal regions
    responsible for binding Insulin like Growth Factors I and II (IGF I and IGF II).
    Most circulating IGFs are in complexes with IGFBPs, which are believed to increase
    the residence of IGFs in the body, modulate availability of IGFs to target receptors
    for IGFs, reduce insulin like effects of IGFs, and act as signaling molecules
    independently of IGFs. About 75% of circulating IGFs are in 1500 220 KDa complexes
    with IGFBP3 and ALS. Such complexes are too large to pass the endothelial barrier.
    The remaining 20 25% of IGFs are bound to other IGFBPs in 40 50 KDa complexes.
    IGFs are released from IGF:IGFBP complexes by proteolysis of the IGFBP. IGFs become
    active after release, however IGFs may also have activity when still bound to
    some IGFBPs. IGFBP1 is enriched in amniotic fluid and is produced in the liver
    under control of insulin (insulin suppresses production). IGFBP1 binding stimulates
    IGF function. It is unknown which if any protease degrades IGFBP1. IGFBP2 is enriched
    in cerebrospinal fluid; its binding inhibits IGF function. IGFBP2 is not significantly
    degraded in circulation. IGFB3, which binds most IGF in the body is enriched in
    follicular fluid and found in many other tissues. IGFBP 3 may be cleaved by plasmin,
    thrombin, Prostate specific Antigen (PSA, KLK3), Matrix Metalloprotease-1 (MMP1),
    and Matrix Metalloprotease-2 (MMP2). IGFBP3 also binds extracellular matrix and
    binding lowers its affinity for IGFs. IGFBP3 binding stimulates the effects of
    IGFs. IGFBP4 acts to inhibit IGF function and is cleaved by Pregnancy associated
    Plasma Protein A (PAPPA) to release IGF. IGFBP5 is enriched in bone matrix; its
    binding stimulates IGF function. IGFBP5 is cleaved by Pregnancy Associated Plasma
    Protein A2 (PAPPA2), ADAM9, complement C1s from smooth muscle, and thrombin. Only
    the cleavage site for PAPPA2 is known. IGFBP6 is enriched in cerebrospinal fluid.
    It is unknown which if any protease degrades IGFBP6.   View original pathway at
    [http://www.reactome.org/PathwayBrowser/#DIAGRAM=381426 Reactome].
  keywords:
  - (factor IIa)
  - 'p-LAMB2 '
  - 'p-CKAP4 '
  - IGF:IGFBP4
  - 'p-APP '
  - 'PAPPA2 '
  - 'APLP2 '
  - IGFBP4
  - 'PDIA6 '
  - 'p-TF '
  - 'Factor V precursor '
  - 'p-PCSK9 '
  - 'p-SCG2 '
  - 'NUCB1 '
  - 'p-EVA1A '
  - 'p-WFS1 '
  - 'CTSG '
  - 'IL6 '
  - 'APOA5 '
  - 'HSP90B1 '
  - 'AFP '
  - 'p-IGFBP4 '
  - 'SERPINC1 '
  - 'KLK3 '
  - 'MEN1 '
  - 'APOL1 '
  - 'p-MEN1 '
  - 'p-NUCB1 '
  - 'p-LAMB1 '
  - 'CST3 '
  - 'p-AMTN '
  - 'p-VGF '
  - 'p-CHRDL1 '
  - 'PCSK9 '
  - 'DMP1 '
  - 'RCN1 '
  - 'IGFBP6 '
  - PAPPA,PAPPA2
  - 'p-CP '
  - 'C3 '
  - 'KLK1 '
  - 'TGOLN2 '
  - 'TIMP1 '
  - 'p-QSOX1 '
  - 'p-SDC2 '
  - 'p-AMELX '
  - 'p-MATN3 '
  - 'NOTUM '
  - 'APOE '
  - 'SPP1 '
  - 'p-ITIH2 '
  - 'p-AMBN '
  - 'p-C4A '
  - 'p-PENK '
  - 'CDH2 '
  - IGFBP3(125-233)
  - 'MELTF '
  - IGF:IGFBP6
  - 'KLK2 '
  - 'p-IGFBP1 '
  - 'DNAJC3 '
  - 'IGFBP2 '
  - 'APOA2 '
  - 'EVA1A '
  - IGFBP1
  - 'p-ADAM10 '
  - 'p-PROC '
  - 'PROC '
  - 'p-LGALS1 '
  - 'FGG '
  - 'p-MXRA8 '
  - 'SERPINA10 '
  - Plasmin
  - IGFBP6
  - FAM20C:FAM20C
  - 'p-KTN1 '
  - 'AMTN '
  - ADP
  - 'p-HRC '
  - IGFBP3(227-291)
  - 'BMP4 '
  - 'VGF '
  - 'p-APOA2 '
  - 'p-GAS6 '
  - 'p-IGFBP3 '
  - 'p-P4HB '
  - 'p-LTBP1 '
  - 'AHSG '
  - 'p-MGAT4A '
  - 'p-APOL1 '
  - 'p-FSTL1 '
  - 'p-FSTL3 '
  - 'p-ANO8 '
  - 'PENK '
  - 'p-CSF1 '
  - IGF:IGFBP5:ALS
  - 'p-IGFBP7 '
  - 'p-MEPE '
  - 'thrombin light chain '
  - 'CYR61 '
  - 'FSTL1 '
  - 'p-GOLM1 '
  - IGFBP3(291-187)
  - 'IGF1 '
  - 'PLG(20-580) '
  - 'p-IGFBP5 '
  - 'QSOX1 '
  - 'p-FGA '
  - 'p-AHSG '
  - 'p-FGG '
  - 'p-Factor V precursor '
  - IGF:IGFBP2
  - 'p-TMEM132A '
  - IGFBP3(28-126)
  - 'p-KNG1 '
  - 'AMBN '
  - 'p-SHISA5 '
  - 'p-SERPINC1 '
  - 'ENAM '
  - ATP
  - 'p-RCN1 '
  - 'p-VWA1 '
  - 'p-APOA5 '
  - IGFBP4(22-156)
  - 'p-CYR61 '
  - 'p-CST3 '
  - 'FSTL3 '
  - IGFBP3(28-186)
  - 'p-MIA3 '
  - 'MMP2(110-660) '
  - 'C4A '
  - 'CHGB '
  - 'p-LAMC1 '
  - 'SERPIND1 '
  - 'p-C3 '
  - 'p-BPIFB2 '
  - 'p-SERPIND1 '
  - 'p-FBN1 '
  - 'p-GPC3 '
  - 'p-SERPINA10 '
  - 'MATN3 '
  - 'SPARCL1 '
  - IGFBP5
  - FAM20C:Phosphorylated FAM20C substrates
  - 'LAMC1 '
  - 'IGFBP4 '
  - IGFBP5(21-163)
  - 'p-APOA1 '
  - 'MIA3 '
  - FAM20C:FAM20A
  - 'IGFBP7 '
  - 'p-SERPINA1 '
  - 'PRKCSH '
  - 'WFS1 '
  - 'CP '
  - 'ITIH2 '
  - 'HRC '
  - 'VCAN '
  - 'MBTPS1 '
  - 'PAPPA '
  - 'SCG3 '
  - 'p-NOTUM '
  - 'p-SPARCL1 '
  - 'p-MBTPS1 '
  - IGFBP2
  - IGFBP3(28-168)
  - 'APOB(28-4563) '
  - IGFBP3(28-124)
  - Prostate Specific
  - 'STC2 '
  - 'GAS6 '
  - 'p-FUCA2 '
  - 'p-CHGB '
  - IGF:IGFBP1
  - 'p-PNPLA2 '
  - 'KTN1 '
  - 'p-SPP2 '
  - IGFBP3(127-291)
  - 'GOLM1 '
  - 'SDC2 '
  - 'p-SCG3 '
  - IGFALS
  - 'ANO8 '
  - 'FBN1 '
  - 'p-IL6 '
  - 'p-ENAM '
  - MMP1,2
  - 'p-BMP15 '
  - 'LGALS1 '
  - 'FGF23 '
  - IGF:IGFBP3:ALS
  - 'p-BMP4 '
  - 'p-FGF23 '
  - IGF1,2
  - 'MGAT4A '
  - 'SHISA5 '
  - 'p-TNC '
  - 'thrombin heavy chain '
  - 'p-ALB '
  - Antigen
  - IGFBP3(125-187)
  - 'APOA1 '
  - IGFBP4(157-237)
  - 'p-VCAN '
  - 'PRSS23 '
  - 'AMELX '
  - 'PNPLA2 '
  - 'TF '
  - 'MSLN '
  - 'FGA '
  - 'SERPINA1 '
  - 'CKAP4 '
  - 'p-DMP1 '
  - 'APP '
  - IGFBP3(188-291)
  - 'p-DNAJC3 '
  - 'KLK13 '
  - 'p-CALU '
  - 'MFGE8 '
  - 'LTBP1 '
  - 'p-PRKCSH '
  - 'p-PRSS23 '
  - 'p-APOE '
  - 'TMEM132A '
  - 'SPP2 '
  - 'TNC '
  - 'P4HB '
  - 'LAMB1 '
  - 'CHRDL1 '
  - 'MXRA8 '
  - 'p-AFP '
  - 'p-APLP2 '
  - 'IGF2(25-91) '
  - Cathepsin G
  - 'GZMH '
  - 'VWA1 '
  - 'SCG2 '
  - 'IGFBP1 '
  - 'p-APOB(28-4563) '
  - IGFBP3(234-291)
  - 'KNG1 '
  - 'MEPE '
  - IGFBP3(169-226)
  - 'FAM20A '
  - IGFBP3
  - activated thrombin
  - 'p-MFGE8 '
  - 'GPC3 '
  - 'ALB '
  - 'p-TIMP1 '
  - 'CSF1 '
  - IGFBP5(164-272)
  - substrates
  - 'ADAM10 '
  - 'FN1 '
  - 'p-TGOLN2 '
  - 'FUCA2 '
  - 'CALU '
  - 'Ca2+ '
  - 'LAMB2 '
  - 'IGFBP3 '
  - 'p-CDH2 '
  - 'p-STC2 '
  - 'BPIFB2 '
  - 'p-HSP90B1 '
  - 'FAM20C '
  - 'p-MSLN '
  - 'PLG(581-810) '
  - 'MMP1(100-469) '
  - 'p-MELTF '
  - 'p-SPP1 '
  - 'BMP15 '
  - 'IGFALS '
  - 'p-FN1 '
  - 'p-PDIA6 '
  - 'IGFBP5 '
  license: CC0
  name: Regulation of IGF transport and uptake by IGF binding proteins
seo: CreativeWork
title: Regulation of IGF transport and uptake by IGF binding proteins
wpid: WP2799
---